IMMP - Immutep - Relatively Unknown Pure Play On LAG3 Surrounded By Major Pharma; Positioned Well For Large Biobucks Deal Or Takeout
- This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc.
- As clinical data continues to strengthen, Immutep is seemingly well situated for potential takeout or large biobucks deal(s).
- Like anti-PD1 (Keytruda, Opvido) & anti-CLTA4 (Yervoy), LAG3 may be a key checkpoint in oncology. Yet, unlike PD1/CTLA4, LAG3 is unique in that both its activation & inhibition kills cancer.
- Efti's combination with KEYTRUDA has been driving strong responses and has the potential to expand KEYTRUDA’s patient population and extend its IP life from 2028 to 2036 across numerous, large indications.
- Early data for efti in combination with Pfizer and Merck KGaA's anti-PDL1 (avelumab) also impressive, and data for efti combination with chemotherapy could represent a game-changer in chemo-immunotherapy approaches.
For further details see:
Immutep - Relatively Unknown Pure Play On LAG3 Surrounded By Major Pharma; Positioned Well For Large Biobucks Deal Or Takeout